This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (4)  • Contact me when this article is cited  Related Content  • Related letters  • Similar articles in this journal  Topic Collections  • Drug Therapy, Other  • Gastroenterology, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Dario Sorrentino, MD; Giovanni Terrosu, MD; Claudio Avellini, MD; Stefania Maiero, MD

Arch Intern Med. 2007;167(16):1804-1807.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Postsurgical recurrence of Crohn disease is a very frequent event, and none of the drugs used for the purpose has really shown a clear-cut efficacy.¹ Infliximab, a monoclonal antibody anti–tumor necrosis factor (antiTNF-), is very effective in the treatment of active Crohn disease, but its benefit in preventing postoperative recurrence is still unknown. Yet, its impact, both medical and economic, could be major.² Local injection of infliximab for early mucosal postoperative recurrence of Crohn disease seems feasible and safe; however, preliminary results have been disappointing.³ By contrast, a patient treated with intravenous infliximab immediately after surgery to prevent the recurrence of colonic Crohn disease has been disease free for 48 months after surgery.⁴

Methods

In the present prospective pilot study, infliximab was administered 2 weeks after surgery, along with low-dose methotrexate, whereas controls were treated with mesalamine alone. . . . [Full Text of this Article]

Results

Comment

AUTHOR INFORMATION


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTERS

Risks of Combining Immunosuppressive and Biological Treatments in Inflammatory Bowel Disease
Xavier Roblin and Jean Marc Phelip
Arch Intern Med. 2008;168(6):667.
EXTRACT | FULL TEXT  

Risks of Combining Immunosuppressive and Biological Treatments in Inflammatory Bowel Disease—Reply
Dario Sorrentino, Giovanni Terrosu, and Claudio Avellini
Arch Intern Med. 2008;168(6):667-668.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Risks of Combining Immunosuppressive and Biological Treatments in Inflammatory Bowel Disease
Roblin and Phelip
Arch Intern Med 2008;168:667-667.
FULL TEXT  

Risks of Combining Immunosuppressive and Biological Treatments in Inflammatory Bowel Disease--Reply
Sorrentino et al.
Arch Intern Med 2008;168:667-668.
FULL TEXT